BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

713 related articles for article (PubMed ID: 32405753)

  • 1. Hepatobiliary MR contrast agent uptake as a predictive biomarker of aggressive features on pathology and reduced recurrence-free survival in resectable hepatocellular carcinoma: comparison with dual-tracer 18F-FDG and 18F-FCH PET/CT.
    Mulé S; Chalaye J; Legou F; Tenenhaus A; Calderaro J; Galletto Pregliasco A; Laurent A; Kharrat R; Amaddeo G; Regnault H; Tacher V; Kobeiter H; Itti E; Luciani A
    Eur Radiol; 2020 Oct; 30(10):5348-5357. PubMed ID: 32405753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pilot comparison of 18F-fluorodeoxyglucose and 18F-fluorocholine PET/CT to predict early recurrence of unifocal hepatocellular carcinoma after surgical resection.
    Fartoux L; Balogova S; Nataf V; Kerrou K; Huchet V; Rosmorduc O; Talbot JN
    Nucl Med Commun; 2012 Jul; 33(7):757-65. PubMed ID: 22504293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative correlation between uptake of Gd-BOPTA on hepatobiliary phase and tumor molecular features in patients with benign hepatocellular lesions.
    Reizine E; Amaddeo G; Pigneur F; Baranes L; Legou F; Mulé S; Zegai B; Roche V; Laurent A; Rahmouni A; Calderaro J; Luciani A
    Eur Radiol; 2018 Oct; 28(10):4243-4253. PubMed ID: 29721686
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative information from gadobenate dimeglumine-enhanced MRI can predict proliferative subtype of solitary hepatocellular carcinoma: a multicenter retrospective study.
    Ding F; Huang M; Ren P; Zhang J; Lin Z; Sun Y; Liang C; Zhao X
    Eur Radiol; 2024 Apr; 34(4):2445-2456. PubMed ID: 37691080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiation of focal nodular hyperplasia from hepatocellular adenoma: Role of the quantitative analysis of gadobenate dimeglumine-enhanced hepatobiliary phase MRI.
    Roux M; Pigneur F; Calderaro J; Baranes L; Chiaradia M; Tselikas L; Decaens T; Costentin C; Laurent A; Azoulay D; Mallat A; Zafrani ES; Rahmouni A; Luciani A
    J Magn Reson Imaging; 2015 Nov; 42(5):1249-58. PubMed ID: 25851028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18 F-FDG PET/MR imaging in patients with suspected liver lesions: Value of liver-specific contrast agent Gadobenate dimeglumine.
    Kirchner J; Sawicki LM; Deuschl C; Grüneisen J; Beiderwellen K; Lauenstein TC; Herrmann K; Forsting M; Heusch P; Umutlu L
    PLoS One; 2017; 12(7):e0180349. PubMed ID: 28683109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of Early Posttreatment PET/CT Evaluation Using FDG or
    Reizine E; Chalaye J; Mule S; Regnault H; Perrin C; Calderaro J; Laurent A; Amaddeo G; Kobeiter H; Tacher V; Itti E; Luciani A
    AJR Am J Roentgenol; 2022 Feb; 218(2):359-369. PubMed ID: 34494448
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatocellular Carcinoma: Retrospective Evaluation of the Correlation Between Gadobenate Dimeglumine-Enhanced Magnetic Resonance Imaging and Pathologic Grade.
    Huang X; Xiao Z; Zhang Y; Lin N; Xiong M; Huang X; Chen Q; Cao D
    J Comput Assist Tomogr; 2018; 42(3):365-372. PubMed ID: 29369947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positron emission tomography/computed tomography with 18F-fluorocholine improve tumor staging and treatment allocation in patients with hepatocellular carcinoma.
    Chalaye J; Costentin CE; Luciani A; Amaddeo G; Ganne-Carrié N; Baranes L; Allaire M; Calderaro J; Azoulay D; Nahon P; Seror O; Mallat A; Soussan M; Duvoux C; Itti E; Nault JC
    J Hepatol; 2018 Aug; 69(2):336-344. PubMed ID: 29518452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline and Post-treatment 18F-Fluorocholine PET/CT Predicts Outcomes in Hepatocellular Carcinoma Following Locoregional Therapy.
    Wallace MC; Sek K; Francis RJ; Samuelson S; Ferguson J; Tibballs J; Asad A; Preen DB; MacQuillan G; Garas G; Adams LA; Jeffrey GP
    Dig Dis Sci; 2020 Feb; 65(2):647-657. PubMed ID: 31440998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gadoxetic acid-enhanced MRI as a predictor of recurrence of HCC after liver transplantation.
    Lee S; Kim KW; Jeong WK; Kim MJ; Choi GH; Choi JS; Song GW; Lee SG
    Eur Radiol; 2020 Feb; 30(2):987-995. PubMed ID: 31471754
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative prediction of microvascular invasion of hepatocellular carcinoma using
    Hyun SH; Eo JS; Song BI; Lee JW; Na SJ; Hong IK; Oh JK; Chung YA; Kim TS; Yun M
    Eur J Nucl Med Mol Imaging; 2018 May; 45(5):720-726. PubMed ID: 29167923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can positron emission tomography with the dual tracers [11 C]acetate and [18 F]fludeoxyglucose predict microvascular invasion in hepatocellular carcinoma?
    Cheung TT; Chan SC; Ho CL; Chok KS; Chan AC; Sharr WW; Ng KK; Poon RT; Lo CM; Fan ST
    Liver Transpl; 2011 Oct; 17(10):1218-25. PubMed ID: 21688383
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive Value of 18F-FDG PET/CT for Vascular Invasion in Patients With Hepatocellular Carcinoma Before Liver Transplantation.
    Lin CY; Liao CW; Chu LY; Yen KY; Jeng LB; Hsu CN; Lin CL; Kao CH
    Clin Nucl Med; 2017 Apr; 42(4):e183-e187. PubMed ID: 28114226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative Fluorine 18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Prediction of Microvascular Invasion in Small Hepatocellular Carcinoma.
    Kobayashi T; Aikata H; Honda F; Nakano N; Nakamura Y; Hatooka M; Morio K; Morio R; Fukuhara T; Masaki K; Nagaoki Y; Kawaoka T; Tsuge M; Hiramatsu A; Imamura M; Kawakami Y; Ohdan H; Awai K; Chayama K
    J Comput Assist Tomogr; 2016; 40(4):524-30. PubMed ID: 26966955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-to-muscle ratio of 8F-FDG PET for predicting histologic features and recurrence of HCC.
    Baek YH; Lee SW; Jeong YJ; Jeong JS; Roh YH; Han SY
    Hepatogastroenterology; 2015; 62(138):383-8. PubMed ID: 25916068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of FDG-PET in the evaluation and staging of hepatocellular carcinoma with comparison of tumor size, AFP level, and histologic grade.
    Wolfort RM; Papillion PW; Turnage RH; Lillien DL; Ramaswamy MR; Zibari GB
    Int Surg; 2010; 95(1):67-75. PubMed ID: 20480845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative PET-CT is useful for predicting recurrent extrahepatic metastasis of hepatocellular carcinoma after resection.
    Morio K; Kawaoka T; Aikata H; Namba M; Uchikawa S; Kodama K; Ohya K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Imamura M; Nakamura Y; Akagi M; Awai K; Kobayashi T; Ohdan H; Chayama K
    Eur J Radiol; 2020 Mar; 124():108828. PubMed ID: 31955034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 11C-acetate and 18F-fluorodeoxyglucose positron emission tomography/computed tomography dual imaging for the prediction of response and prognosis after transarterial chemoembolization.
    Park S; Kim TS; Kang SH; Kim HB; Park JW; Kim SK
    Medicine (Baltimore); 2018 Sep; 97(37):e12311. PubMed ID: 30212970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.